-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanubrutinib in Secondary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanubrutinib in Secondary CNS Lymphoma Drug Details: Zanubrutinib (Brukinsa) acts as an antineoplastic agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cell Therapy For Coronavirus Disease 2019 (COVID-19), Alopecia Areata And Type 1 Diabetes in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cell Therapy For Coronavirus Disease 2019 (COVID-19), Alopecia Areata And Type 1 Diabetes in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LHF-535 in Arenaviridae Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LHF-535 in Arenaviridae Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LHF-535 in Arenaviridae InfectionsDrug Details:LHF-535 is under development for the treatment of arenaviridae...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TLD-1433 in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TLD-1433 in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TLD-1433 in Non Muscle Invasive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalpiciclib in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalpiciclib in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dalpiciclib in Oral Cavity (Mouth) CancerDrug Details:Dalpiciclib isethionate (Erlikon) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulevostinag in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ulevostinag in Oral Cavity (Mouth) CancerDrug Details:Ulevostinag (MK-1454) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Chronic Lymphocytic Leukemia (CLL)...
-
Product Insights
PWD Malaysia – Muara Lassa Bridge – Sarawak
Equip yourself with the essential tools needed to make informed and profitable decisions with our PWD Malaysia - Muara Lassa Bridge - Sarawak report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Company Profile
Inovio Pharmaceuticals Inc – Company Profile
Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several...
Add to Basket -
Company Profile
GeoVax Labs Inc – Company Profile
GeoVax Labs Inc (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. It has partnerships for preclinical and clinical testing with various government, academic and corporate...
Add to Basket